A biotechnology startup operating in New York City is publicly making the case that the worldwide prohibition on creating genetically modified babies deserves a second look, arguing that the possible rewards of editing out disease-causing genes in human embryos may now outweigh the dangers that led to the ban.
The company, Origin Genomics, opened its laboratories to NPR for an exclusive tour, though its founder and chief executive, Cathy Tie, requested that the precise location be kept secret for security reasons. The visit offered a rare look inside a venture that sits at the center of one of the most fiercely debated questions in modern science.
Tie, dressed in a white lab coat embroidered with her name and the company's logo, guided an NPR reporter, photographer and videographer through the facility. She described the work underway there as an effort to demonstrate that gene editing can be used responsibly on human embryos.
The company's mission, according to its own framing, is to prove that the benefits of its technology for repairing defective genes in human embryos are significant enough to justify the risks. That proposition runs directly against the prevailing international consensus, which has treated the creation of gene-edited babies as a line that must not be crossed.
Inside the lab, Tie put on blue rubber gloves and led the group to a gray metal tank resembling an oversized thermos sitting on the floor. She identified it as a cryogenic storage unit filled with liquid nitrogen, the vessel where the company keeps its embryos.
When Tie opened the black lid, white vapor from the liquid nitrogen drifted into the air. She then carefully withdrew a long metal rod, its end holding frosted glass tubes. Four tubes rested in the container, she explained, and each one is capable of holding as many as ten embryos.
Those embryos carry mutations that cause disease. They were donated by couples whose families have suffered for generations from life-threatening genetic disorders, a history that gives the research a deeply personal dimension.
Later in the reporting, a husband and wife who contributed some of the embryos described their hope of one day having healthy children with the assistance of gene editing. Their story illustrates the human stakes behind a debate that is often conducted in abstract terms about ethics, regulation and the limits of science.
To carry out its experiments, Origin's scientists extract stem cells from the donated embryos. The company is using those cells to test its technology for repairing genes that are responsible for serious inherited conditions.
The scientific and ethical questions raised by such work are enormous. Editing the genes of an embryo changes the DNA of every cell that will develop from it, and those alterations would be passed down to future generations. That heritable quality is what distinguishes embryo editing from other forms of genetic medicine and what has prompted widespread calls for restraint.
More than one country has moved to criminalize the practice, and scientific bodies around the world have urged a moratorium. The current landscape took shape in part after a Chinese researcher shocked the international community by announcing the births of twin girls whose embryos he had edited, an episode that intensified demands for strict oversight.
Despite that climate, Origin Genomics is pressing ahead with research it says is aimed at preventing suffering rather than enhancing human traits. The distinction between treating disease and pursuing enhancement is central to how supporters of embryo editing defend the work, though critics argue the boundary is difficult to enforce in practice.
Tie's company is not alone in exploring the technology, but it is unusual in openly urging a reconsideration of the legal bans that govern it. The startup's leadership contends that the science has advanced enough that a blanket prohibition may be doing more harm than good.
Opponents counter that the technology remains too unpredictable, that the long-term consequences of altering the human germline are unknown, and that legalizing the practice could open the door to a market in designed children accessible only to those who can afford it.
The embryos stored in Origin's liquid nitrogen tank represent both sides of that argument. For the families who donated them, they are a possible path to ending a cycle of inherited illness. For regulators and ethicists, they are a reminder of how quickly laboratory capabilities are outpacing the rules meant to govern them.
How the debate unfolds could shape the future of reproductive medicine. If Origin Genomics succeeds in making its case, it may push governments to revisit laws that currently make the creation of gene-edited babies a crime. If it fails, the episode may reinforce the consensus that such work should remain off limits.
For now, the company's labs continue to operate, its scientists continue to study the cells drawn from donated embryos, and the broader question of whether the world should reconsider its prohibition remains unresolved.
(0)